Cure8 research brief
Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness and safety.
Adults with moderately to severely active ulcerative colitis, patients on or considering biologics/IL-23 inhibitors, IBD clinicians, and researchers interested in real-world biologic outcomes.
This retrospective analysis included 257 adults starting mirikizumab across 21 Polish centres, using an intravenous induction (300 mg at weeks 0, 4, 8) with optional extension to week 24 for some patients. The study measured clinical, endoscopic, and laboratory markers at baseline, week 12, and week 24.
The authors report improvements in clinical remission and response rates, endoscopic response, and reductions in inflammatory markers through week 24; corticosteroid-free remission rates and adverse event frequencies are also provided. Safety events were recorded and described as generally favourable.
The report is an abstract-based summary of a multicentre retrospective cohort rather than a randomized trial, so it reflects real-world practice and includes many treatment-exposed patients.
This summary is grounded in the article abstract (structured-content depth: abstract). The study is retrospective and observational, which can include selection bias and lacks randomized comparison. Reported rates reflect the study cohort and follow-up to week 24; longer-term outcomes and head-to-head comparisons are not provided here.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...
